Brean Capital Downgrades Vivus (VVUS) to Sell, Low Qsymia Coverage Means Low Sales
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 14
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 14
Join SI Premium – FREE
Brean Capital downgraded Vivus (NASDAQ: VVUS) from Hold to Sell with a $7 price target, suggesting more than 50% downside.
The firm notes still just 1 in 5 patients are covered by insurance for Qsymia, creating "sticker shock" among patients even with free low dose drug offered by the company.
On the Get Started! program for free low dose Qsymia, management indicated that it is likely to alter it sometime after January. The firm quips "it cannot get cheaper than free, and all that has been learned since launch indicates that paying more certainly will not reduce prescription abandonment."
On the REMS modifications proposed by the company, the firm notes "we have yet to find a drug that had its REMS altered so soon after launch, and clearly Vivus has not sold enough drug for long enough to possibly have generated data arguing against the current REMS."
The firm lowered 4Q12 Qsymia revenue estimate to $2 million and have cut future estimates as well.
The firm notes Arena (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) will have larger salesforces, with Orexigen having the best mix of efficacy, safety, CVOT data, and salesforce strength, and with far more minor competition from Arena, in their view.
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $14.32 yesterday.
The firm notes still just 1 in 5 patients are covered by insurance for Qsymia, creating "sticker shock" among patients even with free low dose drug offered by the company.
On the Get Started! program for free low dose Qsymia, management indicated that it is likely to alter it sometime after January. The firm quips "it cannot get cheaper than free, and all that has been learned since launch indicates that paying more certainly will not reduce prescription abandonment."
On the REMS modifications proposed by the company, the firm notes "we have yet to find a drug that had its REMS altered so soon after launch, and clearly Vivus has not sold enough drug for long enough to possibly have generated data arguing against the current REMS."
The firm lowered 4Q12 Qsymia revenue estimate to $2 million and have cut future estimates as well.
The firm notes Arena (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) will have larger salesforces, with Orexigen having the best mix of efficacy, safety, CVOT data, and salesforce strength, and with far more minor competition from Arena, in their view.
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $14.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades Molson Coors (TAP) to Sell, 'Cycling 2023 Could Be a Mountain Too Hard to Climb'
- BofA Securities Downgrades CEMEX (CX) to Neutral
- Piper Sandler Downgrades Independent Bank Group (IBTX) to Underweight, 'Expectations of Slower NII Recovery'
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
